Shanghai Cancer Center

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

Retrieved on: 
Jeudi, mars 28, 2024
B-cell lymphoma, Plasma, Shanghai Cancer Center, Rituximab, Apoptosis, Leukemia, International Journal of Hematology, Patient, Hospital, Doxorubicin, Vincristine, Fudan University, CC3, Standard of care, Acute myeloid leukemia, Epidemiology, Biomedical Chromatography, Prednisone, Peripheral T-cell lymphoma, PARP, National Cancer Center, Therapy, MYC, BTK, Safety, BeiGene, CDK9, Cyclophosphamide, DLBCL, Canadian International Council, MCL1, Follicular lymphoma, Pharmaceutical industry

The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.

Key Points: 
  • The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.
  • This study will be the first combination trial conducted by a Chinese biotech to combine CDK9 inhibitor and BTK inhibitor targeting DLBCL.
  • The trials of GFH009 treating peripheral T-cell lymphoma and acute myeloid leukemia have entered into phase II stage in China and the U.S. respectively.
  • Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025, Leukemia & Lymphoma, 2021
    3.

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Retrieved on: 
Mercredi, mars 6, 2024
Biotechnology, Other Health, Health, General Health, Women, Pharmaceutical, Oncology, Research, Consumer, Science, Clinical Trials, Progression-free survival, Fudan University, Shanghai Cancer Center, ISD, PARP, ESGO, BRCA, HKEX, Platelet, OS, Gynecologic Oncology (journal), Ovarian cancer, SGO, Patient, Congress, Development, Niraparib, Pharmaceutical industry

“Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.

Key Points: 
  • “Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.
  • “We look forward to sharing the final OS findings from this study at both the 2024 ESGO and SGO conferences.
  • The final OS analysis was conducted after ≥ 50% of OS events occurred in the intent-to-treat population.
  • No new safety signals were identified during the long-term follow up period subsequent to the primary analysis.

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Retrieved on: 
Mercredi, décembre 13, 2023
Quality of life, Axitinib, Shanghai Cancer Center, Everolimus, RECIST, HKEX, Fudan University, Sintilimab, RCC, TTR, Patient, Safety, Pharmaceutical industry

HONG KONG, Shanghai and FLORHAM Park, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“ HUTCHMED ”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.

Key Points: 
  • HONG KONG, Shanghai and FLORHAM Park, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“ HUTCHMED ”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.
  • The study is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of advanced RCC.
  • The primary endpoint is progression free survival (“PFS”) per RECIST 1.1 as assessed by blinded independent central review (BICR).
  • If favorable, the results would enable a New Drug Application submission to China’s National Medical Products Administration (“NMPA”).

Luoxin Pharmaceutical's LX-039 (Innovative Anti-Tumor Drug): Phase I Clinical Study Data Presented at ESMO 2023

Retrieved on: 
Lundi, octobre 23, 2023
MTD, PD, ESMO, Shanghai Cancer Center, SERD, Fluoroestradiol F-18, Congress, Fudan University, Research, Pharmacokinetics, ER, Safety, Patient, Fulvestrant, Therapeutic index, Pharmaceutical industry, Medical imaging

LX-039, an innovative anti-tumor drug developed by Luoxin Pharmaceuticals Group Stock Co., Ltd. (Luoxin Pharmaceutical), was selected for poster presentation at the 2023 ESMO Annual Congress.

Key Points: 
  • LX-039, an innovative anti-tumor drug developed by Luoxin Pharmaceuticals Group Stock Co., Ltd. (Luoxin Pharmaceutical), was selected for poster presentation at the 2023 ESMO Annual Congress.
  • ESMO is one of the most influential oncology conferences globally, attracting over 30,000 professionals every year from more than 150 countries and regions.
  • The Congress covers basic research, translational research, and the latest advancements in clinical studies, providing an exchange platform in clinical diagnosis, treatment, and academic discussions.
  • The study was led by Professor Hu Xichun from Fudan University Shanghai Cancer Center.

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

Retrieved on: 
Lundi, octobre 16, 2023
Congress, Capecitabine, Sintilimab, Nanjing Medical University, HKEX, The First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Xinjiang Medical University, European Society for Medical Oncology, Oncology, Fudan University, Maintenance, Shanghai Cancer Center, Radiation, Patient

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain.
  • Details of the presentations are as follows:
    Fruquintinib plus Sintilimab in patients with either treatment naïve or previously treated advanced gastric or gastroesophageal junction adenocarcinoma: results from a multicenter, single-arm phase Ib/II study
    Xiaoli Wei, Harbin Medical University Cancer Hospital, Harbin, China
    First report of the safety/tolerability and preliminary antitumor activity of fruquintinib plus capecitabine versus capecitabine as maintenance treatment for metastatic colorectal cancer: an open-label, randomized phase Ib/II study
    Wenhua Li, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
    Fuxiang Zhou, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
    Lu Wang, Liver surgery department, Fudan University Shanghai Cancer Center, Shanghai, China
    Pei Ma, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress

Retrieved on: 
Mercredi, février 22, 2023
Maintenance, NORA, Congress, Development, ESMO, Shanghai Cancer Center, III, Placebo, MD, PDS, European Society for Medical Oncology, ADP, Ovarian cancer, Peking Union Medical College, Survival, Data analysis, OS, MOS, Peking Union Medical College Hospital, Mutation, Progression-free survival, ISD, IDS, Fudan University, Medicine, Borat Subsequent Moviefilm, PFS, Oncology, Pharmaceutical industry, Patient, Niraparib

One presentation will feature an ad hoc interim OS data analysis of the Phase 3 NORA trial, showing how niraparib maintenance therapy with an individualized starting dose (ISD) provided a favorable OS (OS; secondary endpoint) trend versus placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of biomarker status.

Key Points: 
  • One presentation will feature an ad hoc interim OS data analysis of the Phase 3 NORA trial, showing how niraparib maintenance therapy with an individualized starting dose (ISD) provided a favorable OS (OS; secondary endpoint) trend versus placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of biomarker status.
  • The median overall survival (mOS) in the niraparib-treated group was numerically higher (46.3 months) compared to 43.4 months in placebo [HR=0.82; 95% CI, 0.56-1.21].
  • This new data analysis explores the treatment effect of niraparib versus placebo on OS adjusted for subsequent poly (ADP-ribose) polymerase inhibitor (PARPi) use in the placebo group.
  • Another presentation will feature a post hoc analysis from the randomized, double-blind, placebo-controlled Phase 3 PRIME trial, with results showing niraparib associated with improved progression-free survival (PFS) regardless of surgical timing and residual disease status compared with placebo in patients with newly diagnosed advanced ovarian cancer in China.

Concord Medical Announces the Successful Holding of the Second Annual Academic Meeting with the world well-known MD Anderson

Retrieved on: 
Mercredi, novembre 16, 2022
Monroe Dunaway Anderson, Anderson, Fudan University, Forward-looking statement, Meeting, University, Company, Nursing management, Education, NYSE, CCM, Research, Phrase, The Meeting, Patient, Radiation, Renji Hospital, Hospital, Shanghai Cancer Center, Oncology, MD Anderson Cancer Center, Method, Ruijin Hospital, Cancer, Pharmaceutical industry, Medical device, Medical imaging, Immunotherapy, Bedside

12 experts from MD Anderson participated in the Meeting, including nine of which as guest speakers and three as moderators and opening speakers.

Key Points: 
  • 12 experts from MD Anderson participated in the Meeting, including nine of which as guest speakers and three as moderators and opening speakers.
  • Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "I would like to express my heartfelt thanks to the experts who spoke on and participated in the Meeting.
  • MD Anderson is one of the best-known cancer treatment centers globally and the largest cancer center in the United States.
  • Leveraging years of strategic cooperation, MD Anderson and Shanghai Concord Cancer Center successfully cohosted the First Annual Academic Meeting in November 2021.

Photocure: Partner announces First Patient Procedure with Hexvix in China under Special Access Program

Retrieved on: 
Lundi, décembre 27, 2021
Cystoscopy, Technology, State Council, Knowledge, Patient, Cancer, Oslo Stock Exchange, OSE, Cell, CEO, Death, Carcinoma in situ, ASA, Neoplasm, Bladder cancer, Diagnosis, Shanghai Cancer Center, Solution, Urology, BLC, Population, BC, NMIBC, Central China, Prevalence, Recurrence, CIS, Medical device, Medical imaging, Pharmaceutical industry, Hexyl aminolevulinate hydrochloride, T4, MIBC, Photocure

Asieris communicated that Hexvix received its first prescription in China by Hainan General Hospital and the first patient procedure was completed on December 26.

Key Points: 
  • Asieris communicated that Hexvix received its first prescription in China by Hainan General Hospital and the first patient procedure was completed on December 26.
  • The first clinical use of Hexvix in China under the special access program was supported by an online conference to engage Urology experts.
  • Asieris will continue to advance the launch of Hexvix in China, allowing patients to benefit from this cutting-edge diagnostic technology as early as possible.
  • In the release, Professor Ye commented "Hexvix provides a new option for the diagnosis and treatment of bladder cancer.

Photocure: Partner announces First Patient Procedure with Hexvix in China under Special Access Program

Retrieved on: 
Lundi, décembre 27, 2021
Cystoscopy, Technology, State Council, Knowledge, Patient, Cancer, Oslo Stock Exchange, OSE, Cell, CEO, Death, Carcinoma in situ, ASA, Neoplasm, Bladder cancer, Diagnosis, Shanghai Cancer Center, Solution, Urology, BLC, Population, BC, NMIBC, Central China, Prevalence, Recurrence, CIS, Medical device, Medical imaging, Pharmaceutical industry, Hexyl aminolevulinate hydrochloride, T4, MIBC, Photocure

Asieris communicated that Hexvix received its first prescription in China by Hainan General Hospital and the first patient procedure was completed on December 26.

Key Points: 
  • Asieris communicated that Hexvix received its first prescription in China by Hainan General Hospital and the first patient procedure was completed on December 26.
  • The first clinical use of Hexvix in China under the special access program was supported by an online conference to engage Urology experts.
  • Asieris will continue to advance the launch of Hexvix in China, allowing patients to benefit from this cutting-edge diagnostic technology as early as possible.
  • In the release, Professor Ye commented "Hexvix provides a new option for the diagnosis and treatment of bladder cancer.